Viracta Therapeutics Inc Stock News
$0.16
3.55%
yesterday
Nasdaq,
Nov 25, 10:00 pm CET
Viracta Therapeutics Inc Stock News
Neutral
GlobeNewsWire
●
13 days ago
- Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) -
Positive
InvestorPlace
●
3 months ago
Viracta Therapeutics (NASDAQ: VIRX ) stock is heading higher on Wednesday after the clinical-stage precision oncology company released its Q2 earnings report. The first bit of news boosting VIRX stock higher is its diluted earnings per share of -25 cents.
Neutral
GlobeNewsWire
●
3 months ago
- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val's substantial antitumor activity and generally well-tolerated safety profile -
Neutral
GlobeNewsWire
●
3 months ago
- New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val's substantial antitumor activity and generally well-tolerated safety profile -
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
